21 min listen
How a new kind of drug could change the future of Alzheimer’s
FromThe Decibel
ratings:
Length:
22 minutes
Released:
Apr 16, 2024
Format:
Podcast episode
Description
There are an estimated 650,000 cases of dementia in Canada right now. The last 20 years of research into the treatment of Alzheimer’s have been, as one expert put it, “agonizing.” But a new drug was approved in the United States and is being tested in Canada to see if it can delay or slow the progression of Alzheimer’s symptoms. And it’s giving researchers and patients some hope that a breakthrough could be on the way.Kelly Grant, health reporter for The Globe, has been looking at this drug more closely. She’s on the show today to tell us what these trials mean for patients and the future of Alzheimer’s research.Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
Released:
Apr 16, 2024
Format:
Podcast episode
Titles in the series (100)
Thinking through Quebec’s unvaxxed tax: Quebec is the first jurisdiction in Canada to propose a ‘health contribution’ tax for people who choose not to get vaccinated against COVID-19. This has sparked a debate about whether some government pandemic measures are going too far into the realm of being punitive. Dr. Devon Greyson, an assistant professor at the School of Population and Public Health at the University of British Columbia, has been studying vaccine hesitancy since 2015. They break down the ethical considerations of this controversial piece of proposed public health policy. Editor’s note: An earlier version of this text misidentified Dr. Greyson as an associate professor at the School of Population and Public Health at the University of British Columbia. by The Decibel